

REMARKS / ARGUMENTS

Claims 22-28 were rejected under 35 USC 103(a) over Cools et al. Applicants request reconsideration and withdrawal of this rejection for the reasons that follow.

The present claims require for midostaurine to be administered in cycles to treat FIP1L1-PDGFR α -induced myeloproliferative disease. Each cycle requires the drug to be administered at least half of the days during the first one to six week period followed by a second period of from one to three weeks where the drug is not administered. Although the reference suggests the utility of midostaurin for treating the condition, it is not even alleged to provide a suggestion or motivation to administer midostaurin in cycles – as is required by the present claims. Without such motivation or suggestion, the present claims are patentable over the relied upon art. Therefore, Applicants request reconsideration and withdrawal of the rejection under 35 USC 103 over Cools et al.

Entry of this response and reconsideration and allowance of the claims are respectfully requested.

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: 28 October 08